Home | Publications | Prescription Drugs place holder
place holder place holder

Prescription Drugs

The Worldwide Prescription Drug Market 2004


Publication Date   November 2001
Publisher   Fuji-Keizai
Product Type   Strategic Report
Pages   133
ISBN Number   not applicable
Product Code   FUJ011
Ask a question about this product?

Price £545.00

approximately: $1,079 | €693

Summary


This report is about the worldwide market for human prescription drugs as it transitions through 2003. The study provides readers with recent information and analysis about key developments driving the industry. The research reviews the broad areas of major company activities ranging from planning new drugs with disease demographics, through to strategic alliances, and market forecasts. The report reviews the challenges of patent expirations, developing new drug pipelines and what companies must do to get their drugs approved around the world. A review of price/cost aspects and drug distribution approaches uncovers the kinds of business activities that the pharma companies must do the market their products through to the end patients in different countries.

The worldwide pharmaceutical industry is complex to all the business participants as well to the end patients. The report works from the standpoint of disease categories and unravels what the key health issues are through disease demographic data from around the globe. The study looks at what disease categories of the top 276 drug products that the drug companies are selling and ranks the best selling areas and products.

This study has found that the market size for worldwide human drugs at yearend 2002 was about $430 billion. Despite the current weak global economy, the market is projected to grow to about $543 billion in 2005 with a CAGR of about 8.1%. The pharmaceutical industry faces numerous challenges that could be helped with newer business approaches. The report discusses these important items with interesting and useful findings. This study uses more than 48 figures and tables to illustrate the findings. Detailed information about the activities of the top companies important to this market is listed in numerous areas of this report.

Content


  • 1. Major Disease Populations in the Developed World
    • 1.1 Disease Based Pharmaceutical Planning
    • 1.2 The Size of Major Disease Populations
    • 1.1Relationship of 'Modern' Lifestyle to Health Risk Factors
  • 2. Regulatory Issues By Disease: Drug Development &Sales
    • 2.1 Government Drug Regulatory Organizations
    • 2.2 The Basic Drug Development and Approval Processes
    • 2.3 North America
      • 2.3.1 The FDA's Drug Review Steps
    • 2.4 European Union (EU)
      • 2.4.1 Overview of the Drug Approval Process in the European Union
      • 2.4.2 Principle of 'Mutual Recognition'
      • 2.4.3 The Centralized Drug Approval Procedure
      • 2.4.4 Decentralized Drug Approval Procedure
    • 2.5 Japan
      • 2.5.1 Japan's Drug Approval Process
      • 2.5.2 Approval Applications for Drugs Manufactured in Foreign Countries
      • 2.5.3 Priority Review System
      • 2.5.4 Orphan Drugs
    • 2.6 Analysis of Regional Issues to Consider
      • 2.6.1 North America
      • 2.6.2 Europe
      • 2.6.3 Japan
  • 3. Current Drug Patent Expiration Date and New Drug Pipeline in Development By Disease
    • 3.1 Near Term Drug Patent Expirations are making an Impact
    • 3.2 Prescription Drug Development Pipeline for Mid-2003
  • 4. Price, Cost & Distribution Structure
    • 4.1 Price/ Cost Structure
    • 4.2 Distribution Structure and Case Study
      • 4.2.1 Distribution Structure
      • 4.2.2 Distribution Case Study
  • 5. Strategic Alliances and M&As By Disease
    • 5.1 Review of Recent Pharmaceutical Strategic Alliances and M&As
    • 5.2 Review of Strategic Alliances and M&As by Disease
    • 5.3 Summary: Strategic Alliances and M&As
    • 5.2About the Data Tables
  • 6. WW Rx Drug Market Size and Forecast by Disease
    • 6.1 Worldwide Prescription Drug Market Size
    • 6.2 Selected WW human Drug Market Size by Disease and Revenues
      • 6.1.1Top Six Market Segments and Sub-Segments
  • 7. Top Selling Rx Drugs by Revenue and Pharmaceutical Companies
    • 7.1 The Top Selling 20 Rx Drugs and Companies
      • 7.1.1 Top Selling 20 Rx Drugs by Disease Categories
      • 7.1.2 Top Selling 20 Rx Drugs by Major Pharma Companies
    • 7.2 Top Selling 276 Rx Drugs by Disease
      • 7.2.1 Summary of Top Disease Categories by WW Revenues
  • 8. Conclusions and Thoughts
    • 8.1 Disease Demographics
      • 8.1.1 Epidemiology Based Pharmaceutical Planning
      • 8.1.2 Reviewing Patient Populations
      • 8.1.3 Health Risk Factors Lead to Sickness & Death
    • 8.2 Key Points about Global Regulators and Issues
      • 8.2.1 Need for Government Drug Regulatory Approval
      • 8.2.2 Regional Drug Development and Approval Processes
      • 8.2.3 Regulatory Trends
    • 8.3 Drug Patent Expiration Dates and New Drug Pipeline
      • 8.3.1 Patent Expirations Looming to Cause Big Losses
      • 8.3.2 Current Drug Development Pipeline is Inadequate
    • 8.4 Price/Cost & Distribution Structures
      • 8.4.1 Price/ Cost Structure
      • 8.4.2 Distribution Structure
    • 8.5 Strategic Alliances and M&As
      • 8.5.1 Alliance Deal Trends
    • 8.6 Prescription Drug Market Size
    • 8.7 Top Selling Rx Drugs and Companies
    • 8.8Final Thoughts
  • 9. Appendix
    • 9.1 Pharmaceutical Business Glossary
    • 9.2 Contacts to Top 50 Pharma Companies
    • 9.3 Links to Worldwide Drug Regulatory Organizations
  • List of Tables
    • Table 1. Summary of Patient Populations Sorted by New Patients
    • Table 2. Summary of Patient Populations Sorted by Total Existing Patients
    • Table 3. Estimated Patient Populations by Disease in the Developed World
    • Table 4. Top Health Risk Factors Leading to Death in the Developed World
    • Table 5. Relationship of Drug Regulation and Drug Development by Disease
    • Table 6. Review of Drug Patent Expirations by Disease Category
    • Table 7. Review of Drug Patent Expirations by Year
    • Table 8. Current Drug Patent Expiration Dates Sorted by Disease
    • Table 9. Drug Pipeline Summary by R&D Phase for 2003
    • Table 10. Drug Pipeline Summary by Disease for 2003
    • Table 11. Prescription Drugs in Late Stage Development by Disease (2003)
    • Table 12. Rx Drug Price/ Cost Structure Tiers by Region
    • Table 13. US Pricing Example for Brand Name Prescription Drugs
    • Table 14. US Major Wholesale Drug Distributor Channel
    • Table 15. US Retail Pharmacy Channel Breakdown
    • Table 16. Major Pharmaceutical Distributors by International Region
    • Table 17. Summary: Pharma Strategic Alliances and M&As by Category
    • Table 18. Summary: Pharma Strategic Alliances and M&As by Disease
    • Table 19. Strategic Alliances and M&As By Disease, 2003
    • Table 20. Strategic Alliances and M&As By Disease, 2002
    • Table 21. Strategic Alliances and M&As By Disease, 2001
    • Table 22. Strategic Alliances and M&As By Disease, 2000
    • Table 23. Total Audited World Rx Drug Sales by Regions, 2002
    • Table 24. Estimated WW Rx Drug Sales by Regions, 2002E-2005E
    • Table 25. Top 10 Products in 2002 Worldwide Pharmaceutical Sales
    • Table 26. Estimated Top 276 Human Prescription Drug WW Market Size Sorted by Revenues ($M) and Disease Segments (Summary), 2002-2005E
    • Table 27. Top 276 Human Prescription Drug WW Market Size Sorted by CAGR and Disease Segments (Summary), 2002-2005E
    • Table 28. Top 276 Human Prescription Drug WW Market Size by Disease Breakdown (Detail) ($M) 2002-2005E
    • Table 29. Top Selling 20 Rx Drugs by WW Revenues 2002 ($M)
    • Table 30. Summary: Top Disease Categories by WW Revenues (2002)
    • Table 31. Definition of Disease Categories Used in this Section
    • Table 32. Rx Drugs Sorted by Disease Indication and WW Revenues
  • List of Figures
    • Figure 1. Drug Development and Approval Process
    • Figure 2. USA FDA New Drug Approval Process Flowchart
    • Figure 3. EU Centralized Drug Approval Procedure Flowchart
    • Figure 4. EU Decentralized New Drug Approval Procedure Flowchart
    • Figure 5. Japan MHLW New Drug Approval Procedure
    • Figure 6. An Rx Drug Distribution Structure
    • Figure 7. Summary: Pharma Strategic Alliances and M&As by Category
    • Figure 8. Summary: Selected M&As by Valuation ($M)
    • Figure 9. Summary: Pharma Strategic Alliances and M&As by Disease
    • Figure 10. Estimated Top 276 Human Prescription Drug WW Market Size by Revenues ($M) and Disease Segments, 2002E-2005E
    • Figure 11. Comparison of Disease Segment Market Shares for the Selected WW Human Prescription Drug Market, 2002 and 2005
    • Figure 12. Estimated Market Size by the 'Cardiovascular' Segment Revenues, 2002-2005
    • Figure 13. Estimated Market Size by 'CNS' Segment Revenues, 2002-2005
    • Figure 14. Estimated Market Size by 'Infections' Sub-Segment Revenues, 2002-2005
    • Figure 15. Estimated Market Size by 'Respiratory & Allergy' Sub-Segment Revenues, 2002-2005
    • Figure 16. Estimated Market Size by the 'Gastrointestinal' Sub-Segment Revenues, 2002-2005
    • Figure 17. Estimated Market Size by the 'Cancer' Sub-Segment Revenues, 2002-2005